6 results about "Formyl peptide receptor" patented technology

Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, solvates, polymorphs, or pharmaceutically acceptable salts thereof: in which each of variables R1, R2, R3, R4, R5, R6 and L is defined herein. Also disclosed are a method for treating disease or disorder mediated by formyl peptide receptor with the compound of formula (I) or a tautomer, stereoisomer, isotopologue, solvate, polymorph, or salt thereof, and a pharmaceutical composition containing same.

The present application provides a polypeptide targeting formyl peptide receptor on the cell membrane surface, a pharmaceutical composition and their applications. The polypeptide targeting formyl peptide receptor on the cell membrane surface includes a ligand of the formyl peptide receptor and Cys or Lys located at the C-terminus of the polypeptide connected to the ligand of the formyl peptide receptor; or, the polypeptide is the ligand of the formyl peptide receptor, and the C-terminus of the ligand of the formyl peptide receptor is Cys or Lys. After the polypeptide stimulates the formyl peptide receptor on the cell membrane surface, the endocytosed formyl peptide receptor cannot be recycled to the cell membrane, thereby targeting and rapidly knocking down the formyl peptide receptor on the cell membrane surface. Moreover, by using this polypeptide to knock down the formyl peptide receptor on the cell membrane surface, there is no need to perform enzymatic modification on the polypeptide additionally, no need to rely on other degradation techniques, and the off-target effects of gene knockout and gene knockdown methods can be avoided. The operation is simple and the effectiveness is high.

The invention discloses a modularized pathogenic microorganism targeting fluorescent probe, an antibacterial drug delivery oligopeptide and a preparation method and application thereof, the probe is composed of the following functional modules: a chemotactic module: formyl-D-Phe-Leu-D-Met, which realizes active migration to an infectious inflammation microenvironment by combining with a formyl peptide receptor; the targeting module comprises D-Trp-D-Trp-Arg and RWWR which are specifically combined with the surfaces of the pathogenic microorganisms through cationic interaction and hydrophobic interaction; the fluorescence activation module is a double Cy5.5 fluorophore which is covalently connected through lysine side chain amino; and the connection and stability module is a PEG4-GGSG flexible linker, has C-terminal amidation and key site D-type amino acid modification, and is used for enhancing the stability of the probe. The probe can actively migrate to an infectious inflammation microenvironment, is specifically combined with the surface of pathogenic microorganisms, and triggers fluorescence activation after combination, so that accurate imaging of an infected part is realized.

Disclosed are compounds of the following Formula (I) and tautomers, stereoisomers, isotopologues, solvates, polymorphs, or pharmaceutically acceptable salts thereof: Formula (I), wherein each of the variables R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and L are defined below. Also disclosed is a method of treating a disease or disorder mediated by Formyl Peptide Receptor 1 (FPR1) with a compound of Formula (I) or a tautomer, stereoisomer, isotopologue, solvate, polymorph, or pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the same.

A method for treating muscular dystrophy of a subject comprising administrating a N-formyl peptide receptor (FPR) agonist to the subject and compositions therefore. An FPR agonist may be used to target the FPR2-mediated pro-resolving pathway, thus facilitating the clearance of inflammation, reducing inflammatory response, enhancing repair processes, enhancing regenerative capacity in muscles, and otherwise improving prognosis of muscular dystrophy.

The present invention relates to compounds of Formula I, which are formyl peptide receptor 2 (FPR2) receptor agonists. The invention also provides compositions and methods using the compounds, for example, for treating atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.